Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

CHEMED CORP
Next earnings Jul 27, 2026 · consensus $5.68 EPS, $672M rev
Last earnings +2.6% on 2026-04-23
High-ROE hospice/Roto-Rooter compounder with low debt and big buybacks, but FY2025 earnings dipped and 24x leaves it fairly valued.
Sources: SEC EDGAR (CIK 0000019584, latest 10-Q filed 2026-04-28) · EODHD · analysis by claude-code · as of 6/21/2026, 8:56:01 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
Middling fundamentals and a rich price (~61% above fair value) leave little margin of safety — a wait-and-see.
Chemed is a high-quality, two-segment compounder — VITAS (the largest U.S. hospice provider) and Roto-Rooter (plumbing/drain services) — with an exceptional capital-return record. The franchise economics are strong: a 27.1% ROE, 13.4% operating margin, and very low leverage (0.57x liabilities/equity). Revenue grew 4.1% to $2.53B in FY2025, extending a steady multi-year climb, and the company generated $388M of operating cash flow against modest $62.8M capex.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $2.14B | $2.13B | $2.26B | $2.43B | $2.53B |
| Gross profit | — | — | — | — | — |
| Operating income | $343M | $343M | $341M | $366M | $338M |
| Net income | $269M | $250M | $273M | $302M | $265M |
| Diluted EPS | $16.85 | $16.53 | $17.93 | $19.89 | $18.34 |
| Net margin | 12.6% | 11.7% | 12.0% | 12.4% | 10.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1482 tracked peers · median
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Last 90 days: 0 open-market buys · 2 sales
| 2026-06-09 | LINDELL ANDREA R Director | Sell | 1.35K @ $447.33 | $603K |
| 2026-05-29 | WALSH GEORGE J III Director | Sell | 500.00 @ $437.83 | $219K |
| 2026-05-18 | WALSH GEORGE J III Director | Award | 386.00 @ $440.77 | $170K |
| 2026-05-18 | Mount John Meredith Jr. Director | Award | 386.00 @ $440.77 | $170K |
| 2026-05-18 | McCarthy Eileen P Director | Award | 386.00 @ $440.77 | $170K |
| 2026-05-18 | LINDELL ANDREA R Director | Award | 386.00 @ $440.77 | $170K |
| 2026-05-18 | Heaney Christopher J Director | Award | 386.00 @ $440.77 | $170K |
| 2026-05-18 | GRACE PATRICK P Director | Award | 386.00 @ $440.77 | $170K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.